Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04522375
Other study ID # FP045C-19-001
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 30, 2023
Est. completion date December 2025

Study information

Verified date May 2023
Source Foresee Pharmaceuticals Co., Ltd.
Contact Bassem Elmankabadi, MD
Phone 562 310-8718
Email Bassem.elmankabadi@foreseepharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, Phase 1/2 study to determine the Optimal Biologic Dose (OBD) and to evaluate the safety, tolerability, PK, and preliminary activity of FP 045 when administered orally in young adult/adolescent and pediatric patients with Fanconi anemia. The study will enroll a total of 6 young adult/adolescent patients and a minimum of 8 and up to 12 pediatric patients with mild-moderate bone marrow failure who have not undergone hematopoietic cell transplant. This makes the total patient number between 14-18 total. Dose escalation will occur individually for each patient, within each age group. Each patient will receive each of 3 dose levels of FP 045 (intra-patient dose escalation), beginning with Dose Level 1, followed by Dose Levels 2 and 3. Each dose level will be administered for 28 days prior to escalation to the next higher dose level for that patient.


Description:

Dose escalation will begin with young adult/adolescent patients. The initial two patients enrolled in the study will be > 15 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional young adult/adolescent patients being enrolled. All 6 young adult/adolescent patients must complete 28 days of treatment at Dose Level 1, and cumulative safety must be reviewed by the Safety Review Committee (SRC), prior to the enrollment of pediatric patients. The initial two pediatric patients enrolled will be > 6 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional pediatric patients being enrolled. A minimum of 8 and maximum of 12 pediatric patients will be enrolled to allow for at least 4 patients between the ages of 3-6. Study assessments will be conducted at each visit. Patients will be observed closely for Dose Limiting Toxicity (DLT) during each dosing period. Any patient experiencing a DLT will have study drug interrupted and will not be allowed to escalate to the next higher dose level. The patient may resume treatment at one dose level lower once the DLT has resolved to baseline or to ≤ Grade 1 in severity. The MTD will be defined as the dose level immediately below the dose level at which DLT occurred. Patients requiring an interruption in treatment of > 3 weeks following a DLT will be withdrawn from the study. The MTD will be assessed separately for each individual patient. Following the completion of dose escalation, each patient will continue treatment at either the highest dose or their individual MTD, and then transition to the OBD for their age group (once defined), for a total of 3 months. Patients failing to receive 75% of planned doses for reasons other than adverse effects may be replaced.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date December 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 25 Years
Eligibility Inclusion Criteria: - male or female aged 3-25 - documented Fanconi anemia by chromosome breakage analysis - females of child-bearing potential and males required to use highly effective birth control - mild to moderate bone marrow failure with at least one cytopenia of > grade 1 severity Exclusion Criteria: - history of any malignancy except focal squamous cell or basal cell carcinoma of the skin or carcinoma in situ of cervix - has myelodysplastic syndrome or acute leukemia per world health organization (WHO) criteria - has history of any significant medical conditions - has aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5x upper limit of normal (ULN) or calculated creatinine clearance (Clcr) of < 50 mL/min - has active Hepatitis B or C - has an ongoing systemic infection - requires a strong CYP3A4 inhibitor - has had major surgery within 30 days - Active graft versus host disease requiring systemic treatment - Has a history of bone marrow or stem cell transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FP-045
activator of aldehyde dehydrogenase

Locations

Country Name City State
United States St. Jude Childrens Research Hospital Memphis Tennessee
United States Masonic Cancer Center, University of Minnesota Minneapolis Minnesota
United States David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center New York New York
United States Lucille Packard Children's Hospital, Stanford University Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Foresee Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Optimal Biologic Dose (OBP) of FP-045 The OBP of FP-045 in adolescent and pediatric subjects 28 days x up to 3 doses
Primary stabilizing or improving cytopenia in FA Change from baseline in hemoglobin 3 months
Secondary Safety and tolerability Frequency of adverse events and serious adverse events 3-6 months
Secondary pharmacokinetic profile Mean AUC of FP-045 by dose level 3- 6 months
See also
  Status Clinical Trial Phase
Completed NCT02931071 - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1 Phase 2
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT01146210 - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia N/A
Completed NCT01082133 - Multicenter Transplant Study for Fanconi Anemia Phase 2
Completed NCT00965666 - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia Early Phase 1
Terminated NCT00290628 - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer N/A
Recruiting NCT00027274 - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated NCT01001598 - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita Phase 1/Phase 2
Recruiting NCT03206086 - Eltrombopag for People With Fanconi Anemia Phase 2
Recruiting NCT03579875 - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Phase 2
Recruiting NCT05598515 - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia N/A
Active, not recruiting NCT03476330 - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia Phase 2
Terminated NCT05910853 - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT00479115 - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 Phase 1/Phase 2
Completed NCT00352976 - TBI Dose De-escalation for Fanconi Anemia Phase 2/Phase 3
Terminated NCT03600909 - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia Phase 2